The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population
Recruiting · NCT03893929 · Observational (researchers observe without assigning treatment) · Lead sponsor: Chinese University of Hong Kong
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Prostate cancer (PC) is highly prevalent worldwide and is currently the 3rd most commonly diagnosed prostate cancer in Hong Kong male population with more than 1600 new cases diagnosed per year. However, the current use of serum PSA as a diagnostic marker is unsatisfactory. Many patients has elevated serum PSA is actually due to other causes and also the level of serum PSA do not correlate with the staging and grading of prostate cancer. Moreover, the current risk stratification system, based on PSA, clinical staging and Gleason score is of only limited value, as a significant proportion of patients with high-risk nonmetastatic PC have incurable disease due to locally advanced and/or occult metastasis,, whilst others with indolent disease may never suffer morbidity or mortality from PC. Therefore, in order to improve patient management and outcome, there is a need to identify newer markers and also validate some potential markers in Chinese population.
Who can take part
Inclusion criteria
- Adult Chinese male patients with age \> 18 years old
- Clinical suspected to have prostate cancer, based on abnormal digital rectal examination or elevated serum PSA level
Exclusion criteria
- \. Patient refused or unable to provide consent for the study
Where it is running
1 location listed.
- Prince of Wales Hospital - Shatin, Hong Kong